Tesamorelin Peptide Tablets

Muscle atrophy is a clinical syndrome caused by striated muscle dystrophy, characterized by the thinning and reduction of muscle fibers leading to decreased muscle volume and strength. Its pathogenesis is associated with multiple factors including neurogenic injury, myogenic lesions, disuse atrophy, and nutritional and metabolic disorders. This condition not only impairs patients' limb function and self-care ability but also predisposes bedridden patients to severe complications such as pneumonia and pressure ulcers, endangering their life and health. As an innovative oral dosage form of synthetic GHRH analog, Tesamorelin Peptide Tablets demonstrate unique value in the intervention and repair of muscle atrophy through precise regulation of growth hormone (GH) secretion and the advantages of its dosage form, providing a new direction for the clinical management of such chronic diseases.

Prevention and Repair of Disuse Muscle Atrophy

Disuse muscle atrophy is one of the most common clinical types, frequently seen in patients with long-term immobilization after fractures, limb hemiplegia following stroke, and elderly individuals on prolonged bed rest. This type of muscle atrophy does not stem from organic lesions of muscles or nerves but from metabolic imbalance caused by long-term inactivity. Through the regulation of the GH-IGF-1 axis, it can effectively inhibit muscle protein catabolism, promote protein synthesis, and delay or even reverse the process of disuse muscle atrophy.

Meanwhile, the tablet dosage form is convenient for home use during the rehabilitation period, and can produce a synergistic effect when combined with rehabilitation training-rehabilitation training activates muscle contraction function, while it provides physiological support for muscle repair and growth, accelerating muscle strength recovery and shortening the rehabilitation cycle.

Adjuvant Intervention in Neurogenic Muscle Atrophy

Neurogenic muscle atrophy is caused by impaired muscle nutrient supply due to nerve function damage. The core of treatment lies in repairing nerve function and maintaining muscle activity. Although it cannot directly repair damaged nerves, it can provide alternative nutritional support for muscle tissue by supplementing GH and IGF-1, delay muscle fiber degeneration, maintain the basic activity of muscle tissue, and create favorable conditions for nerve repair. In the comprehensive treatment of diseases such as spinal cord injury and peripheral neuritis, Tesamorelin Peptide Tablets can be used as an adjuvant drug, combined with neurotrophic drugs and rehabilitation therapy, to improve muscle strength and limb mobility, thereby enhancing the quality of life.

In addition, its metabolic regulatory effect can improve the nutritional absorption disorders often associated with neurogenic muscle atrophy patients, further optimizing muscle nutrient supply.

Long-term medication may lead to adverse reactions such as joint pain, myalgia, and peripheral edema, most of which are related to elevated GH levels. These reactions are usually mild to moderate and can gradually alleviate after drug withdrawal. Some patients may develop drug antibodies, which affect long-term efficacy. It is necessary to regularly assess drug concentration, muscle strength, and muscle mass changes, and adjust the treatment plan in a timely manner. It should be particularly emphasized that the current application of it in muscle atrophy is mostly exploratory research and has not yet obtained official approval for this specific indication.

Moreover, there is a risk of over-the-counter abuse. Unauthorized use may lead to dosage imbalance, and combined use with testosterone may even cause adverse events such as abnormal organ enlargement. Therefore, all medication must be carried out under the guidance of a physician, strictly following the dosage specifications.

The clinical demand for muscle atrophy treatment is growing day by day. With its unique mechanism of action and dosage form advantages, it are expected to become an important adjuvant drug in the comprehensive treatment of muscle atrophy. Currently, its application in disuse muscle atrophy and HIV-associated muscle atrophy has been supported by partial clinical data. Future research should focus on three main directions: First, conduct large-sample, long-term clinical trials to verify its efficacy in improving muscle mass and strength in patients with different types of muscle atrophy, and clarify the suitable population and optimal dosage regimen.

Second, optimize the bioavailability of the tablet dosage form, adjust the formula according to the physiological characteristics of muscle atrophy patients, and enhance targeting ability. Third, explore the combined application effect of it with rehabilitation training, neurotrophic drugs, and protein supplements to form a multi-dimensional synergistic treatment plan and further improve clinical efficacy.

Synthesis and Early Validation of It (Mid-1990s)

In the mid-1990s, researchers successfully synthesized it through structural optimization based on the amino acid sequence of endogenous GHRH (GHRH1-44). Compared with natural GHRH, it has enhanced chemical stability and receptor-binding affinity through amino acid modification. It can more efficiently and durably simulate the physiological functions of endogenous GHRH, stimulate the pituitary gland to secrete GH in a pulsatile manner, and then activate the downstream insulin-like growth factor-1 (IGF-1) pathway.

Clinical Translation: Clinical Trials and Market Approval (Late 1990s - 2010)

Based on its clear pharmacological advantages, it soon entered the clinical trial phase, focusing on the treatment of HIV-associated visceral fat accumulation. Multiple clinical trials showed that the product can significantly reduce visceral fat area in HIV patients, improve metabolic disorders, and has good safety with mostly mild to moderate adverse reactions.

Dosage Form Iteration: R&D and Optimization of Oral Tablets (After 2010)

The initially marketed it was a subcutaneous injection formulation. Despite its definite efficacy, long-term medication required professional operation, limiting patient compliance, and was associated with adverse reactions such as pain and redness at the injection site. To address these issues, researchers launched the R&D of an oral dosage form, with the core goal of overcoming the bottleneck of low oral bioavailability of peptide drugs-peptide drugs are susceptible to enzymatic hydrolysis in the gastrointestinal tract and subject to hepatic first-pass metabolism, making it difficult for conventional oral dosage forms to exert therapeutic effects.

Subsequent Development: Formulation Optimization and Application Expansion (2010 - Present)

The R&D of it has not stagnated since its launch. In 2025, the FDA approved the supplemental Biologics License Application (sBLA) for the F8 formulation of it. This high-concentration formulation can extend the patient treatment cycle and further improve medication compliance. However, the iterative process also faced challenges. For instance, the F8 formulation once encountered setbacks in its marketing application due to issues such as production processes and microbiological control, but was finally approved after technical improvements, reflecting the complexity of peptide drug formulation R&D.